Overview

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Status:
Terminated
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
Phase:
N/A
Details
Lead Sponsor:
Achillion Pharmaceuticals
Alexion Pharmaceuticals
Treatments:
Dexelvucitabine